Healthcare / BiotechnologyParis
$0.43
-0.01 (-1.39%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-22.5M · quality 70.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
28/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$219M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-66.2%
↓Gross Margin
N/A
•Debt/Equity
0.03
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.95x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-29.4M · FCF $-28.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | — | — | $140050.00 |
| Net Income | $-29.4M | $-29.4M | $-26.0M | $-22.1M | $-23.2M |
| EBITDA | $-29.0M | $-29.0M | $-25.4M | $-21.5M | $-22.3M |
| EPS | -0.10 | -0.10 | -0.09 | -0.18 | -0.29 |
| Operating Margin | — | — | — | — | -16493.6% |
| Net Margin | — | — | — | — | -16572.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.03 | 0.03 | 0.03 | 0.09 | 0.18 |
| Current Ratio | 4.59 | 4.59 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-28.0M | $-28.0M | $-22.5M | $-21.6M | $-22.9M |
| Returns | |||||
| ROE | -66.2% | -66.2% | -36.0% | -66.3% | -106.0% |
| Valuation | |||||
| P/B | 2.87 | 2.87 | 2.56 | 1.97 | 1.36 |
| Growth & Yield | |||||
| EPS Growth | -11.1% | -11.1% | 50.0% | 37.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+3.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.09 → -0.10
Residual
+3.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.